Tucson, Ariz. (September 25, 2013) - The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients.
TUCSON, Ariz. (September 4, 2013) – The National Human Genome Research Institute of the National Institutes of Health issued a Notice of Award granting a Phase II SBIR award of $1.01 million for HTG Molecular Diagnostics to continue the Nuclease Probe Mediated Sequencing Project (HTG EdgeSeq).
TUCSON, Ariz. (July, 2013) – HTG Molecular Diagnostics , today announced the availability of two new multiplexed assays for drug and oncology research, coinciding with the successful completion of the first wave of installations of its MDEA award-winning HTG Edge System.
TUCSON, Ariz. (June, 2013) – The Edge System, developed and commercialized by HTG Molecular Diagnostics, is the 2013 Silver Award recipient for in-Vitro Diagnostics in the 15th Annual Medical Design Excellence Awards competition. The HTG Edge System is the only automated RNA analysis platform that
TUCSON, Ariz. (April, 2013) –The Edge System, developed by HTG Molecular Diagnostics, is a finalist in the 15th Annual Medical Design Excellence Awards competition. HTG Molecular Diagnostics is a privately held company specializing in RNA based diagnostics and solutions for translational research.
TUCSON, Ariz. (November 27, 2012) – The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics have finalized a license agreement that provides HTG Molecular Diagnostics exclusive rights to commercialize PROOF Centre-developed gene expression blood
TUCSON, Ariz. (October 18, 2012) – HTG Molecular Diagnostics will unveil the EDGE system at the AMP conference in Long Beach, October 25 – 27, 2012. The EDGE system is the first fully-automated instrumentation designed for clinical and research laboratories that offers nucleic acid extraction-free
TUCSON, Ariz. (September 13, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Vijay Modur, M.D., Ph.D. as vice president of translational science and chief medical officer. Dr. Modur joins HTG Molecular Diagnostics from Novartis
Demonstrating Internationally Recognized Standards for Quality Management in Provision of Medical Devices and Related Services TUCSON, Ariz. (July 30, 2012) – HTG Molecular Diagnostics, a privately-held company providing products for gene expression profiling, has achieved ISO 13485:2003
TUCSON, Ariz. (July 11, 2012) – HTG Molecular Diagnostics, a privately held, Tucson-based developer of mRNA and miRNA gene expression-based cancer diagnostics, has been granted a non-exclusive license to develop, manufacture, and commercialize breast cancer diagnostic tests under Merck’s patent